Hillel S Panitch

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. ncbi request reprint Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial
    Hillel Panitch
    University of Vermont College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA
    J Neurol Sci 239:67-74. 2005
  2. ncbi request reprint Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial
    H Panitch
    University of Vermont College of Medicine, Burlington, VT 05401, USA
    Neurology 59:1496-506. 2002
  3. ncbi request reprint Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study
    Hillel Panitch
    University of Vermont, College of Medicine, Burlington 05401, USA
    Neurology 63:1788-95. 2004
  4. ncbi request reprint Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis
    Hillel S Panitch
    Neurology Health Care Service, Fletcher Allen Health Care, University of Vermont, Burlington, 05401, USA
    Ann Neurol 59:780-7. 2006
  5. ncbi request reprint Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relap
    Steven R Schwid
    Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
    Clin Ther 29:2031-48. 2007

Detail Information

Publications5

  1. ncbi request reprint Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial
    Hillel Panitch
    University of Vermont College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA
    J Neurol Sci 239:67-74. 2005
    ..The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes...
  2. ncbi request reprint Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial
    H Panitch
    University of Vermont College of Medicine, Burlington, VT 05401, USA
    Neurology 59:1496-506. 2002
    ..Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial...
  3. ncbi request reprint Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study
    Hillel Panitch
    University of Vermont, College of Medicine, Burlington 05401, USA
    Neurology 63:1788-95. 2004
    ..To evaluate the efficacy and safety of interferon beta-1b (IFNbeta-1b) in subjects with secondary progressive multiple sclerosis (SPMS)...
  4. ncbi request reprint Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis
    Hillel S Panitch
    Neurology Health Care Service, Fletcher Allen Health Care, University of Vermont, Burlington, 05401, USA
    Ann Neurol 59:780-7. 2006
    ....
  5. ncbi request reprint Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relap
    Steven R Schwid
    Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
    Clin Ther 29:2031-48. 2007
    ..Interferon (IFN)-beta therapy represents an important advance in the management of relapsing multiple sclerosis (MS), but information about the relative benefits and risks of available preparations is limited...